ライフサイエンスコーパス: survival advantage

1 subvert host innate immune responses for its survival advantage.

2 come in malignant transformation to confer a survival advantage.

3 and let-7 suppressed tumor growth leading to survival advantage.

4 th such changes, in addition to conferring a survival advantage.

5 -/-) mice, unlike F12(-/-) mice, do not have survival advantage.

6 display diminished mitotic errors and have a survival advantage.

7 that increased genetic diversity provides a survival advantage.

8 ic for diseases in which donor cells have no survival advantage.

9 Conversely, mutation of phtD conferred a survival advantage.

10 n within the glioma as well as a substantial survival advantage.

11 importantly, LGP2 TG mice had a significant survival advantage.

12 mma receptors, providing the bacteria with a survival advantage.

13 r of patients with severe sepsis may offer a survival advantage.

14 e cancer (PCa) cells and that this confers a survival advantage.

15 Neighborhood factors slightly moderate this survival advantage.

16 plified, and DeltaNp63alpha confers a potent survival advantage.

17 pporting the concept that ST6Gal-I confers a survival advantage.

18 ute respiratory distress syndrome, regarding survival advantage.

19 th IL-5 family cytokines no longer confers a survival advantage.

20 hat provide a tumor a significant growth and survival advantage.

21 e systems may, in part, explain the Canadian survival advantage.

22 peration is safe and confers a risk-adjusted survival advantage.

23 ly to external stimuli may gain a growth and survival advantage.

24 roversy surrounding the significance of this survival advantage.

25 ovel cotreatment strategies to override this survival advantage.

26 red blood cell ratios were associated with a survival advantage.

27 n of these survival molecules and associated survival advantage.

28 this recovery associates with a significant survival advantage.

29 included an anthracycline, but there was no survival advantage.

30 are increasing despite controversy regarding survival advantage.

31 luding ionizing radiation (IR), leading to a survival advantage.

32 r reptiles, anaphylaxis might even provide a survival advantage.

33 liferator-activated receptor-alpha confers a survival advantage.

34 on and/or ablation was not associated with a survival advantage.

35 use the adaptive ER stress response to gain survival advantage.

36 sociated with PB transplantation may offer a survival advantage.

37 flammatory gut diseases and gains a distinct survival advantage.

38 iven lung cancer, resulting in a significant survival advantage.

39 ough 1,200-1,400 ft conferred an incremental survival advantage.

40 ifferences in signal strength translate into survival advantages.

41 n of the Akt pathway is responsible for cell survival advantages.

42 ansformed phenotype by conferring growth and survival advantages.

43 als in the first-line setting have not shown survival advantages.

44 ectin-like domain of thrombomodulin showed a survival advantage, accompanied by decreased bacterial l

45 prostate stem cells would provide ERG-driven survival advantages, allowing maintenance of this mutate

46 hat warm-adapted species carry a significant survival advantage amidst the synergistic impacts of lan

47 e Recently, a large randomized trial found a survival advantage among patients who received elective

48 e emergency treatment, there was a long-term survival advantage among patients who underwent CABG as

49 ention ICD was associated with a significant survival advantage among women and among men.

50 than single agents but do not demonstrate a survival advantage and are associated with increased tox

51 cellular carcinoma, but the relation between survival advantage and disease etiology remains unclear.

52 nter more and miss less reward, resulting in survival advantage and enhanced evolutionary fitness.

53 There was no survival advantage and heterogeneity was reduced when an

54 isseminated to murine lungs demonstrated the survival advantage and increased colonization ability of

55 e to IR and further imply that p65-dependent survival advantage and initiation of clonal expansion ma

56 not negatively impact the living-donor graft survival advantage and provides similar cumulative graft

57 The survival advantage and relapse protection in C1/x recipi

58 or an MT1-MMP-null allele display a distinct survival advantage and retain myocardial function relati

59 ndings show that education-dependent NK cell survival advantages and killing of uneducated NK cells r

60 enin-positive hepatocytes exhibit growth and survival advantages and repopulate KO livers, eventually

61 on with self-pMHC ligands imparts growth and survival advantages as revealed in thymic stromal cultur

62 The survival advantage associated with TAVR that was seen at

63 However, we did not observe a survival advantage associated with total thyroidectomy c

64 left anterior descending vessels conferred a survival advantage at 15 years compared with SV grafting

65 demonstrated no progression-free or overall survival advantage at 3 years, a European study demonstr

66 tivated B cells, and its ablation provides a survival advantage both in vitro and in vivo.

67 ent's perspective, which integrates not only survival advantage but also disease-associated and adver

68 ds to more compact patches that enhance this survival advantage but also reduce the overall growth.

69 ls to sites of infection but also provides a survival advantage by dampening excessive inflammation t

70 ells and provide the virus with an important survival advantage by manipulating the host immune respo

71 CXCR4 (X4)-, and dual-tropic HIV-1 and had a survival advantage compared to control cells ex vivo In

72 nsplantation was associated with a long-term survival advantage compared to dialysis, but there were

73 ated that PSC patients have a positive graft survival advantage compared to non-PSC patients (hazard

74 ibitor MDV3100 has been reported to confer a survival advantage compared to placebo in the same patie

75 iving donor (LD) recipients had an immediate survival advantage compared to similar risk wait-listed

76 at, in aggregate, has resulted in an overall survival advantage compared with breast-conserving surge

77 mbination therapy might be associated with a survival advantage compared with initial monotherapy in

78 were associated with a small but significant survival advantage compared with moderate-intensity stat

79 OCS3) were associated with a 10- and 6-month survival advantage compared with noncarriers in patients

80 ponses to topotecan, producing a significant survival advantage compared with subjects treated with t

81 No larynx-preservation approach offered a survival advantage compared with total laryngectomy and

82 Surgical interventions confer survival advantages compared with palliative therapies f

83 y alone or combined with cisplatin showed no survival advantage, compared with control groups (all, P

84 nts abrogate this cytotoxicity, indicating a survival advantage conferred by the FAM46C mutant phenot

85 Clinical studies reported a potent survival advantage conferred by the oxazolidinone and ca

86 The survival advantage conferred by treatment with 2C10 prov

87 Despite frequent use, the survival advantage conferred on patients with stage II d

88 node primary tumor did not have disease-free survival advantage despite surgical margin clearance (9

89 dent up-regulation gave Tsc1(null) neurons a survival advantage, despite their misplacement in a nove

90 tial mortality rates than whites, this early survival advantage did not persist during long-term foll

91 6/STAT3 pathway in tumor cells may provide a survival advantage during anti-VEGF treatment, suggestin

92 as well as glucose, for energy, conferring a survival advantage during feast and famine.

93 odel includes known spatial variation in the survival advantage enjoyed by the yellow morph and assum

94 active against a syngeneic AML model with a survival advantage equivalent to doxorubicin plus cytara

95 ls in some regions were not experiencing the survival advantage expected at given levels of mortality

96 As mitochondrial transfer provides a clear survival advantage following chemotherapy and a higher l

97 Heterozygotes experienced >40% absolute survival advantage following two different models of sep

98 rapy, second-line chemotherapy, and reported survival advantage for a CYP (17,20) lyase inhibitor in

99 inhibitor of apoptosis protein, suggesting a survival advantage for ALL cells.

100 The principal objective was to explore survival advantage for an intensified chemotherapy strat

101 ity score-adjusted Cox models demonstrated a survival advantage for bevacizumab-carboplatin-paclitaxe

102 However, the commonly cited survival advantage for black dialysis patients applies o

103 gher social integration is associated with a survival advantage for Blacks and Whites.

104 ndomized phase III data to date supporting a survival advantage for combining molecularly targeted ag

105 The survival advantage for EVAR repair in a statewide popula

106 atabase studies have demonstrated a powerful survival advantage for ICD patients undergoing RM compar

107 There was an early (to discharge) survival advantage for infants before next-stage surgery

108 A survival advantage for overweight and obese patients was

109 There was no survival advantage for patients in the medical-cardiac g

110 nstrumental variables analysis, there was no survival advantage for patients treated in centers where

111 rall, allograft survival analysis revealed a survival advantage for patients who normalize PTH within

112 However, previous studies could not show a survival advantage for patients with AL amyloidosis resp

113 Centralised multidisciplinary care confers a survival advantage for patients with ALS and is superior

114 ey transplantation confers a well-documented survival advantage for patients with end-stage renal dis

115 Social attachment is associated with a survival advantage for patients with ovarian cancer.

116 d might have a small but clinically relevant survival advantage for patients with spontaneous superfi

117 some older patients with MDS, there may be a survival advantage for RIC HSCT compared with nontranspl

118 Previous studies have not shown a survival advantage for smoking reduction.

119 on is superior to remaining on dialysis, the survival advantage for SPK recipients compared to kidney

120 osis, and experience with CML, a significant survival advantage for TH patients (hazard ratio: 0.632

121 oposed transesterification indeed provides a survival advantage for the producing microorganism.

122 rk has evaluated functional improvements and survival advantage for these techniques, although their

123 based on older data demonstrating an overall survival advantage for total thyroidectomy over lobectom

124 by the EGFR/GSTP1 cross-talk and provides a survival advantage for tumors with activated EGFR and hi

125 The average 10% survival advantage for women persisted throughout this p

126 ents at earlier stages explained much of the survival advantages for colon cancer and NSCLC.

127 n elevated frequencies of alleles conferring survival advantages for infectious diseases, but that ar

128 transcription factor T-bet did not gain any survival advantage from RABV infection, exhibiting only

129 te hemoconcentration conferred a significant survival advantage (hazard ratio: 0.74 [95% confidence i

130 surgery compared with surgery alone showed a survival advantage (HR = 0.83, 95% CI 0.76-0.90), wherea

131 ith adjuvant therapies showed no significant survival advantage (HR = 0.87, 95% CI 0.67-1.14).

132 Treatment with EP was not associated with a survival advantage in a Cox proportional hazards model (

133 TTM also provided a survival advantage in a genetically engineered mouse mod

134 n, attenuation of multiple organ damage, and survival advantage in a mouse model of sickle cell disea

135 or effector cell population, Bcl-2 confers a survival advantage in a subset of effector CD8(+) T cell

136 its myeloma cell proliferation, resulting in survival advantage in a systemic myeloma xenograft model

137 There was no survival advantage in association with higher total or p

138 This significant survival advantage in both p53WT and p53null leukemic mi

139 our study demonstrate a significant overall survival advantage in both patients who are clinically n

140 ukemia or lymphoma in xenograft models and a survival advantage in comparison to control mice.

141 Phase III clinical trials showing a survival advantage in CRPC for treatment with abirateron

142 f cytopenias) were not uniformly improved, a survival advantage in favor of ruxolitinib therapy was d

143 ver, the precise mechanisms that confer this survival advantage in females over males are unclear.

144 gy, given that a MEK1/2 inhibitor provides a survival advantage in metastatic melanoma, an effect tha

145 ion with cellulose offers a microbe-mediated survival advantage in murine models of sepsis.

146 l infiltration of tumour islets represents a survival advantage in non-small cell lung cancer (NSCLC)

147 ctive LgtD in a few bacteria could provide a survival advantage in other sites of infection.

148 e is a small, yet statistically significant, survival advantage in patients who have ICP monitors and

149 chemotherapy regimens results in an overall survival advantage in patients with advanced disease who

150 iled to show that beta2AR agonists provide a survival advantage in patients with ALI.

151 an adaptive cellular response that confers a survival advantage in response to sepsis at a cost of de

152 Although these mutations confer a survival advantage in the presence of rifampin, they may

153 to FFP approaching 1:1 are associated with a survival advantage in traumatic hemorrhage, even in pati

154 ific for melanoma cells displayed a relative survival advantage in tumors.

155 Anti-HER2 treatment has clear survival advantages in HER2-positive breast carcinoma pa

156 ntraperitoneal therapy (IP) has demonstrated survival advantages in patients with peritoneal cancers,

157 iology of the host and provide the host with survival advantages in several ways, while they could al

158 ase in copy number of the oncogene, provides survival advantages in solid tumors including malignant

159 This survival advantage is counter-regulated by lipocalin 2,

160 This survival advantage is slightly more pronounced in lower

161 ds or natural or synthetic colloids confer a survival advantage is unclear.

162 F2BP3 provided murine BM cells with a strong survival advantage, led to proliferation of hematopoieti

163 The survival advantage may arise for several postulated reas

164 F suppression, one that suggests a potential survival advantage mechanism for MITF amplification in m

165 By 8 years, this survival advantage more than doubled.

166 rformed prone positioning offers an absolute survival advantage of 10-17%, making this intervention h

167 e disease-modifying medication and confers a survival advantage of 2-3 months.

168 expression of nonfunctional SVs conferred a survival advantage of androgen-dependent LNCaP cells und

169 We examined whether the survival advantage of androgen-deprivation therapy with

170 of human CD4(+) cell levels and a selective survival advantage of anti-HIV gene-modified cells were

171 wn bats (Eptesicus fuscus) and demonstrate a survival advantage of approximately 47% for moths with t

172 The observed survival advantage of bevacizumab was more apparent with

173 related pathways in CTC clusters, suggesting survival advantage of clusters in circulation.

174 The previously reported possible survival advantage of CMV is now statistically significa

175 We show for the first time that there is a survival advantage of DBS surgery in advanced PD.

176 The survival advantage of ET over PV was not affected by JAK

177 Insight into the survival advantage of female patients may advance the mo

178 lating factor (GM-CSF) by MCs that induces a survival advantage of graft-derived DCs.

179 d to break even is 1:20,000; however, if the survival advantage of HSCT before 3 months is confirmed,

180 Despite a significant survival advantage of kidney transplantation compared wi

181 age Liver Disease (MELD) scores <15, and the survival advantage of LDLT has not been demonstrated dur

182 Although the long-term survival advantage of multiple arterial grafting (MAG) v

183 ancer, this work demonstrates that gaining a survival advantage of premalignant cells may delay or pr

184 ntermediate-2 or high IPSS risk have shown a survival advantage of ruxolitinib over placebo (COMFORT-

185 A significant survival advantage of sensitizing AML for chemotherapy w

186 A survival advantage of the DAC arm over the DA arm was ob

187 Correlative analyses confirm that the survival advantage of the proneural subtype is conferred

188 d to demonstrate a statistically significant survival advantage of treatment with tremelimumab over s

189 introduction of oncogenic Ras abrogated the survival advantage of TSC2(-/-) MEFs upon ceramide treat

190 ays resulting from transfer would reduce the survival advantage of X-PCI compared with O-FT.

191 m more rapid production and a cell-intrinsic survival advantage of Zbtb32(-/-) secondary plasma cells

192 (Petrochelidon pyrrhonota) to show that the survival advantages of different colony sizes fluctuated

193 at the WNT pathway confers proliferative and survival advantages on cap cells via regulation of FOXO1

194 other chemotherapy-sensitive STS provides no survival advantage or reduction in the intensity of loca

195 Such a mixotrophic lifestyle would confer survival advantage (or possibly provide a unique narrow

196 t base, termed 'central cells', experience a survival advantage over border stem cells.

197 but whether systematic screening leads to a survival advantage over clinical diagnosis is uncertain.

198 Patients with PSC do not have an independent survival advantage over de novo patients, but present wi

199 t (TCS) devices afford children a meaningful survival advantage over ECMO.

200 R1507 with erlotinib did not provide PFS or survival advantage over erlotinib alone in an unselected

201 layed a significant infection dose-dependent survival advantage over fibrinogen-deficient mice follow

202 m/CDDP) combination has demonstrated a clear survival advantage over gemcitabine alone and has become

203 on on fully mature ASCs provides a selective survival advantage over less mature, newly minted ASCs,

204 omen and children first" (WCF) gives women a survival advantage over men in maritime disasters, and t

205 ptake, and produce metabolites that confer a survival advantage over pathogens.

206 istant prostate cancer (CRPC) demonstrated a survival advantage over placebo.

207 egy for atrial fibrillation does not offer a survival advantage over rate control in heart failure pa

208 rgoing transplantation conferred a long-term survival advantage over remaining on the waitlist, which

209 a negative margin of 1 cm or more confers a survival advantage over subcentimeter negative margins.

210 e showed that WT GBS exhibited a significant survival advantage over the DeltapilA or Deltasrr-1 muta

211 y known as bilateral IMAs (BIMAs) provides a survival advantage over the use of LIMA alone.

212 R(-/-) mice with WT marrow had a significant survival advantage over their counterparts with IFN-alph

213 lomustine plus bevacizumab did not confer a survival advantage over treatment with lomustine alone i

214 Mice lacking the MKP-2 gene had a survival advantage over wild-type mice when challenged w

215 Several studies indicate that PBSCs confer survival advantages over bone marrow with matched siblin

216 bodied species, N. macrotis, and hybrids had survival advantages over the larger-bodied N. fuscipes i

217 Extra margin width did not add disease-free survival advantage (P > 0.05).

218 ailed Fisher test), as well as a significant survival advantage (P = 0.01; hazard ratio = 0.2, time-d

219 we show that primary human monocytes have a survival advantage, proliferate in vivo and develop into

220 The epithelial cell-autonomous survival advantage provided by IDO1 to colon epithelial

221 79) SETD8 inhibition conferred a significant survival advantage, providing evidence for SETD8 as a th

222 identified in the current study offer clear survival advantage, providing fast efficient transformat

223 wild-type N. gonorrhoeae strain FA1090 has a survival advantage relative to a PEA transferase A (lptA

224 ith primitive LSK cells having a significant survival advantage relative to more mature cells, consis

225 However, a substantial survival advantage remains for babies born into wealthie

226 The survival advantage seen in noninteracting combinations s

227 However, it is unclear if this survival advantage stems from the improved intravascular

228 y while providing a glutamine-dependent cell survival advantage, strongly suggests a metabolic surviv

229 ivors, the addition of PCV to RT conferred a survival advantage, suggesting a delayed benefit for che

230 y, and delayed peripheral injection has mild survival advantage, suggesting that early CNS ASO admini

231 men, but black race became associated with a survival advantage, suggesting that racial differences i

232 weight newborns from HbAC mothers may have a survival advantage that contributes to the natural selec

233 rysm was associated with a substantial early survival advantage that gradually decreased over time.

234 about 80-fold while providing a significant survival advantage that improved with greater treatment

235 translation may provide a context-dependent survival advantage that must be considered as a possible

236 ), the combination therapy did not provide a survival advantage; the median overall survival was 9.1

237 growth by providing GAB2-expressing cells a survival advantage through upregulation of BCL-2 family

238 r immune responses, conferring a significant survival advantage to AMD3100-treated mice.

239 If there is a survival advantage to any strategy, it is likely to be s

240 mia (CLL) pathogenesis and gives an in vitro survival advantage to B cells isolated from patients wit

241 we report that loss of p53 did not provide a survival advantage to B cells, as they underwent rapid a

242 Glycolysis provides survival advantage to cancer cells.

243 egulation of survivin and thereby provides a survival advantage to cells exposed to oxidative stress

244 ng a metabolic state that confers a profound survival advantage to cells in poorly vascularized tumou

245 nificantly, overexpression of ECD provided a survival advantage to cells upon ER stress induction.

246 R patients can be avoided, there is no early survival advantage to EVAR.

247 bachia also confers a weak, but significant, survival advantage to flies attacked by L. heterotoma.

248 se mutation in the Miocene likely provided a survival advantage to help maintain glucose levels under

249 tion, and ultimately conferred a significant survival advantage to infected mice.

250 ns, yet it was unknown if LLO could confer a survival advantage to L. monocytogenes in neutrophils.

251 We found a strong survival advantage to larger eggs and faster juvenile me

252 survival following TAC, it did not confer a survival advantage to mice following aortocaval shunt.

253 ion of nelfinavir and consequently conferred survival advantage to nelfinavir cytotoxicity.

254 c prescription of beta-blockers may confer a survival advantage to patients who subsequently develop

255 that this metabolic reprogramming provided a survival advantage to photoreceptors in an experimental

256 Interestingly, bioluminescence conferred a survival advantage to the bacteria following ara-C treat

257 lter host immune responses, thus providing a survival advantage to the bacterium.

258 tutive JAK2 activation provides a growth and survival advantage to the hematopoietic cells of the aff

259 ntibiotics have long been assumed to yield a survival advantage to the producing bacteria in the high

260 s antigen-presenting pathway would provide a survival advantage to the virus.

261 ssociated with transplantation may provide a survival advantage to transplant recipients with sepsis

262 prevalent oncogenic alterations and confers survival advantage to tumor cells.

263 , suggesting that PRL-3 provides a strategic survival advantage to tumour cells via its effects on mT

264 ose Small observational studies have shown a survival advantage to undergoing cancer-directed surgery

265 f lipogenesis in providing proliferative and survival advantages to cancer cells has been described,

266 r such reversible adhesion probably provides survival advantages to the bacteriophage.

267 hat leads to reduced ROS levels and provides survival advantages to the white cells.

268 c oncogene, given that it confers growth and survival advantages to these cells, whereas its inhibiti

269 nly by the acquisition of SVs that provide a survival advantage under castrate conditions, enabling r

270 lylglycine-treated BMDACs have a significant survival advantage under conditions of low O(2) and low

271 iated DNA DSBs, thereby providing cells with survival advantages under conditions of replication stre

272 f Myc oncogene, whereas mutant cells empower survival advantage upon overgrowth and glucose deprivati

273 Women's survival advantage was markedly diminished in hemodialys

274 The survival advantage was not observed when absolute dense

275 No significant survival advantage was observed in IPAH patients who sta

276 In our cecal slurry model, no survival advantage was seen among matrix metalloproteina

277 A modestly more pronounced survival advantage was seen for foreign-born Hispanics l

278 An overall survival advantage was seen with maintenance olaparib ve

279 scription (STAT) pathway provides cells with survival advantage, we wondered whether BCR stimulation

280 Increased expression of AAC-11 confers a survival advantage when cancer cells are challenged with

281 ound histones displayed more than a fourfold survival advantage when challenged with four different b

282 rix metalloproteinase-8 null intestine had a survival advantage when compared with mice receiving wil

283 a negative margin of 1 cm or more confers a survival advantage when compared with subcentimeter nega

284 8 null mice receiving wild-type marrow had a survival advantage when compared with wild-type mice rec

285 with high-risk phenotypes, which gave them a survival advantage when exposed to predators.

286 acids and glucose, TSC2(-/-) MEFs also had a survival advantage when extracellular amino acids and gl

287 der basal conditions, it provided a powerful survival advantage when proteasome function was impaired

288 nditions, and thus they inherently possess a survival advantage when suspended.

289 is adaptation occurs too slowly to provide a survival advantage when there is a sudden change in envi

290 These patient subsets demonstrate a survival advantage when treated with coronary artery byp

291 a's northward spread by 76 km, and that this survival advantage will persist under future climates.

292 gest reported follow-up show a breast cancer survival advantage with 10-year durations of tamoxifen u

293 There is insufficient evidence to support a survival advantage with a 1:1 plasma to packed red blood

294 D-1 antibody bound T cells and demonstrate a survival advantage with addition of a TIM-3 blocking ant

295 t trials of PCI vs. CABG demonstrated a late survival advantage with anatomy-based CABG.

296 After multivariable adjustment, there was no survival advantage with AVR in asymptomatic, severe AS w

297 The perioperative survival advantage with endovascular repair was sustaine

298 Conclusion We found a modest survival advantage with higher intake of protein, regard

299 modulates the host immune response to gain a survival advantage within the host.

300 , we found that aggressive individuals had a survival advantage within their nest, but foundress grou